Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Mar 30, 2026
Reporting period
Not applicable
Filed with the SEC
Apr 2, 2026
CEOOption exercise
Context
Classification
option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001635088-26-000034
Filed / recorded
Apr 2, 2026, 3:20 AM UTC
Added to OQRO
Oct 6, 2026, 8:46 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Roivant Sciences Ltd.
Issuer CIK
1635088
Ticker
ROIV
Reporting person
Matthew Gline
Relationship
Director, Officer
Officer title
CEO
Security
Capped Value Appreciation Rights
Table
Derivative (Table II)
Transaction date
Mar 30, 2026
Transaction code
M
Shares / units
2,178,150
Price per share
$11.50
Acquired / disposed
Disposed (D)
Shares owned after
0
Ownership form
Direct
Amendment
No
Footnotes from the filing
Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").
On March 30, 2026, the hurdle price applicable to 2,178,150 vested CVARs was satisfied and, accordingly, the CVARs were settled into 97,319 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026.
